PET/MR评估骨转移的国际专家意见声明
该国际专家意见声明基于同行评议文献及13家主要PET/MR中心专家的经验,总结PET/MR在骨骼转移评估中的应用价值。声明指出,[18F]-FDG和非[18F]-FDG PET/MR在多种原发恶性肿瘤的骨转移评估中可能较PET/CT具有关键优势,建议在原发肿瘤特征提示骨转移可能性高、临床高度怀疑且骨转移会影响患者管理时考虑使用PET/MR。
要点
- PET/MR结合MR软组织对比度与PET分子信息,独特适用于骨骼转移评估。
- 在原发肿瘤特征提示骨转移高可能、临床高度怀疑时,可考虑PET/MR分期。
- 应选择肿瘤特异性放射性药物并严格遵循PET和MR协议。
核心结论
- PET/MR应被考虑用于原发肿瘤特征提示骨转移可能性高、临床高度怀疑且骨转移会影响患者管理的恶性肿瘤分期。
研究设计与样本
- 国际专家意见声明,基于同行评议文献检索及13家主要PET/MR中心专家的意见、实践和协议。
主要发现
- [18F]-FDG和非[18F]-FDG PET/MR在多种原发恶性肿瘤的骨转移评估中可能较PET/CT提供关键优势。
临床怎么用
- 在原发肿瘤特征提示骨转移高可能、临床高度怀疑且骨转移会影响患者管理时,可考虑使用PET/MR进行分期。
- 应选择肿瘤特异性放射性药物,并严格遵循PET和MR协议。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: MR is an important imaging modality for evaluating musculoskeletal malignancies owing to its high soft tissue contrast and its ability to acquire multiparametric information. PET provides quantitative molecular and physiologic information and is a critical tool in the diagnosis and staging of several malignancies. PET/MR, which can take advantage of its constituent modalities, is uniquely suited for evaluating skeletal metastases. We reviewed the current evidence of PET/MR in assessing for skeletal metastases and provided recommendations for its use. METHODS: We searched for the peer reviewed literature related to the usage of PET/MR in the settings of osseous metastases. In addition, expert opinions, practices, and protocols of major research institutions performing research on PET/MR of skeletal metastases were considered. RESULTS: Peer-reviewed published literature was included. Nuclear medicine and radiology experts, including those from 13 major PET/MR centers, shared the gained expertise on PET/MR use for evaluating skeletal metastases and contributed to a consensus expert opinion statement. [18F]-FDG and non [18F]-FDG PET/MR may provide key advantages over PET/CT in the evaluation for osseous metastases in several primary malignancies. CONCLUSION: PET/MR should be considered for staging of malignancies where there is a high likelihood of osseous metastatic disease based on the characteristics of the primary malignancy, hight clinical suspicious and in case, where the presence of osseous metastases will have an impact on patient management. Appropriate choice of tumor-specific radiopharmaceuticals, as well as stringent adherence to PET and MR protocols, should be employed.
引用
- Husseini JS, Amorim BJ, Torrado-Carvajal A, et al. An international expert opinion statement on the utility of PET/MR for imaging of skeletal metastases. Eur J Nucl Med Mol Imaging. 2021. PMID: 33619599. doi:10.1007/s00259-021-05198-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。